‘Real world’ injectable treatment halves patient dissatisfaction, with only two viral failures in first six months
European Commission approves first twice-yearly HIV medication
Long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression
New formulations and alternative injection sites might allow self-administration of long-acting cabotegravir and rilpivirine
Injectable cabotegravir plus rilpivirine every two months maintains viral suppression for three years, but carries higher risk of treatment failure
Top 5 HIV treatment stories from CROI 2022
Lenacapavir shows continued promise for first-line treatment and highly resistant HIV
Trials of long-acting islatravir for HIV treatment and prevention placed on hold
First injectable therapy for HIV approved for England and Wales
